Neurocognitive deficits are a core feature of schizophrenia and, therefore, represent potentially critical outcome variables for assessing antipsychotic treatment response. We performed genome-wide association studies (GWAS) with 492K single nucleotide polymorphisms (SNPs) in a sample of 738 patients with schizophrenia from the Clinical Antipsychotic Trials of Intervention Effectiveness study. Outcome variables consisted of a neurocognitive battery administered at multiple time points over an 18-month period, measuring processing speed, verbal memory, vigilance, reasoning, and working memory domains. Genetic mediation of improvements in each of these five domains plus a composite neurocognitive measure was assessed for each of five antipsyc...
Genetic factors may underlie beneficial and adverse responses to antipsychotic treatment. These rela...
ImportanceThe Consortium on the Genetics of Schizophrenia (COGS) uses quantitative neurophysiologica...
Background: Understanding individual differences in the development of extrapyramidal side effects (...
Neurocognitive deficits are a core feature of schizophrenia and, therefore, represent potentially cr...
Schizophrenia is an often devastating neuropsychiatric illness. Understanding the genetic variation ...
Examine the unique and congruent findings between multiple raters in a genome-wide association studi...
BackgroundTherapeutic treatments for schizophrenia do not alleviate symptoms for all patients and ef...
The search for biomarkers of response to antipsychotic medications is hindered by difficulties inher...
Recent important advancements in genomic research have opened the way to new strategies for public h...
ImportanceSchizophrenia is associated with widespread cognitive impairments. Although cognitive defi...
This study assessed genetic contributions to six cognitive domains, identified by the MATRICS Cognit...
Patients with schizophrenia frequently display neurocognitive dysfunction, and genetic studies sugge...
Importance: Schizophrenia is associated with widespread cognitive impairments. Although cognitive de...
Abstract Using successful genome-wide association results in psychiatry for drug repurposing is an o...
Background: Genome-wide association studies (GWAS) have significantly contributed to the association...
Genetic factors may underlie beneficial and adverse responses to antipsychotic treatment. These rela...
ImportanceThe Consortium on the Genetics of Schizophrenia (COGS) uses quantitative neurophysiologica...
Background: Understanding individual differences in the development of extrapyramidal side effects (...
Neurocognitive deficits are a core feature of schizophrenia and, therefore, represent potentially cr...
Schizophrenia is an often devastating neuropsychiatric illness. Understanding the genetic variation ...
Examine the unique and congruent findings between multiple raters in a genome-wide association studi...
BackgroundTherapeutic treatments for schizophrenia do not alleviate symptoms for all patients and ef...
The search for biomarkers of response to antipsychotic medications is hindered by difficulties inher...
Recent important advancements in genomic research have opened the way to new strategies for public h...
ImportanceSchizophrenia is associated with widespread cognitive impairments. Although cognitive defi...
This study assessed genetic contributions to six cognitive domains, identified by the MATRICS Cognit...
Patients with schizophrenia frequently display neurocognitive dysfunction, and genetic studies sugge...
Importance: Schizophrenia is associated with widespread cognitive impairments. Although cognitive de...
Abstract Using successful genome-wide association results in psychiatry for drug repurposing is an o...
Background: Genome-wide association studies (GWAS) have significantly contributed to the association...
Genetic factors may underlie beneficial and adverse responses to antipsychotic treatment. These rela...
ImportanceThe Consortium on the Genetics of Schizophrenia (COGS) uses quantitative neurophysiologica...
Background: Understanding individual differences in the development of extrapyramidal side effects (...